14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $31.23 $31.23 Wednesday, 1st May 2024 IMGN stock ended at $31.23. During the day the stock fluctuated 0% from a day low at $31.23 to a day high of $31.23.
90 days $29.21 $31.25
52 weeks $10.31 $31.25

Historical ImmunoGen prices

Date Open High Low Close Volume
Sep 26, 2023 $14.83 $15.07 $14.74 $14.97 2 617 101
Sep 25, 2023 $14.79 $14.79 $14.50 $14.63 2 599 789
Sep 22, 2023 $14.97 $14.97 $14.47 $14.77 2 363 790
Sep 21, 2023 $14.50 $15.10 $14.41 $14.93 3 833 887
Sep 20, 2023 $15.73 $15.74 $14.60 $14.64 3 845 578
Sep 19, 2023 $15.68 $16.01 $15.62 $15.67 3 081 473
Sep 18, 2023 $15.55 $15.86 $15.22 $15.71 4 006 593
Sep 15, 2023 $15.34 $15.88 $15.30 $15.72 7 508 535
Sep 14, 2023 $15.83 $15.98 $15.58 $15.76 3 769 386
Sep 13, 2023 $16.05 $16.44 $15.86 $15.88 5 323 720
Sep 12, 2023 $15.66 $15.89 $15.38 $15.45 2 507 158
Sep 11, 2023 $15.71 $15.94 $15.63 $15.67 2 477 414
Sep 08, 2023 $15.46 $15.97 $15.46 $15.70 1 935 005
Sep 07, 2023 $15.49 $15.63 $15.17 $15.49 1 874 657
Sep 06, 2023 $15.55 $15.83 $15.47 $15.59 2 687 761
Sep 05, 2023 $15.80 $15.90 $15.27 $15.46 2 915 021
Sep 01, 2023 $16.04 $16.22 $15.87 $15.92 2 496 476
Aug 31, 2023 $15.98 $16.00 $15.62 $15.84 2 193 789
Aug 30, 2023 $16.10 $16.21 $15.73 $15.93 2 186 970
Aug 29, 2023 $15.99 $16.28 $15.66 $15.99 3 596 200
Aug 28, 2023 $15.00 $15.71 $14.81 $15.54 4 553 021
Aug 25, 2023 $15.90 $16.25 $15.68 $16.13 2 410 096
Aug 24, 2023 $16.48 $16.48 $15.82 $15.90 2 381 550
Aug 23, 2023 $16.69 $16.75 $16.22 $16.25 3 170 486
Aug 22, 2023 $16.09 $16.57 $16.09 $16.50 2 248 507
Click to get the best stock tips daily for free!

About ImmunoGen

ImmunoGen ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and... IMGN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT